摘要
目的:研究溶血磷脂酸受体2(LPAR2)在乳腺癌组织中的表达,并分析其与乳腺癌预后之间的相关性。方法:收集乳腺癌患者癌组织及癌旁组织,利用实时定量PCR及免疫组化染色技术检测乳腺癌及癌旁组织中LPAR2 m RNA及蛋白的表达,回顾性分析乳腺癌患者临床病理资料及预后生存状态与LPAR2表达的相关性。结果:72%(64/89)乳腺癌患者癌组织中LPAR2的表达高于癌旁组织,实时定量PCR定量分析显示乳腺癌组织LPAR2表达升高具有显著统计学意义(P<0.001)。乳腺癌组织中LPAR2的表达与患者的年龄、BMI、肿瘤分级、肿瘤大小及ER、PR、HER2表达无相关性(P>0.05);但肿瘤分期越晚,LPAR2的表达越高(P<0.001),且乳腺癌淋巴结转移患者的LPAR2的表达显著高于非转移患者(P<0.001)。此外,癌组织中LPAR2高表达的患者无进展生存期显著小于无LPAR2高表达的患者(52.7±5.46 vs.64.3±3.09,P=0.016)。结论 :LPAR2在乳腺癌组织中表达显著升高,且可作为判断乳腺癌预后的标志物。
Objective To explore the expressions of lysophosphatidic acid receptor 2 （LPAR2） in breast cancer and analyzed the correlation of LPAR2 to prognosis of breast cancer patients. Methods Human breast cancer tissues and pericancerous normal breast tissues were collected and the mRNA and protein expression of LPAR2 were evaluated using immunohistochemistry and real-time PCR. Then, the relationship between LPAR2 and elinicopathological factors and survival were analyzed by appropriate statistical method. Results 72% of patients showed higher expression of LPAR2 in cancerous tissues than in pericancerous normal tissues. The mRNA expression of LPAR2 was significantly higher in breast cancer （P〈0.001）. LPAR2 expression was not correlated with age, BMI, tumor grade, size, and expression of ER, PR, and HER2 （P〈O.05）. However, the LPAR2 overexpression was associated with tumor stage and lymphatic metastasis （P〈0.001）. Moreover, over-expression of LPAR2 in cancerous tissues indicated a poor prognosis of breast cancer patients. Conclusion LPAR2 was over-expressed in breast cancer tissues and might be a poor prognostic factor of breast cancer patients.
出处
《实用医学杂志》
CAS
北大核心
2015年第10期1590-1593,共4页
The Journal of Practical Medicine
